Cary J. Claiborne - 29 May 2025 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ADIL
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 16:01:31 UTC
Prior SEC filing: 05 Dec 2024
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Cary J. Claiborne

Key filing fact

Cary J. Claiborne filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 02 Jun 2025.

Key facts

This page summarizes Cary J. Claiborne's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2025, 16:01.

Change

Previous filing in this sequence was filed on 05 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370930 Primary reporting owner

Claiborne Cary J

Relationship: Chief Executive Officer, Director
Address: 4870 SADLER ROAD,, STE 300, GLEN ALLEN,
Signature: /s/ Cary J. Claiborne
Signature date: 02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +138,000
Change %
Price: $0.000000
Shares after: 138,000
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 138,000
Exercise price: $0.6880
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .